^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Biliary Tract Cancer

    Related cancers:
    3d
    Safety and efficacy of albumin-bound paclitaxel in combination with immunotherapy as second-line treatment for malignant biliary tract tumors (ChiCTR2600116737)
    P=N/A, N=40, Not yet recruiting, the Second Affiliated Hospital of Nanchang University; the Second Affiliated Hospital of Nanchang University
    New trial
    |
    albumin-bound paclitaxel
    3d
    The significance of lymph node ratio among radically-resected cases with biliary tract cancers: ASEER-based retrospective cohort study (ChiCTR2500112957)
    P=N/A, N=2528, Completed, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New trial
    3d
    A Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping (ChiCTR2500111407)
    P=N/A, N=55, Not yet recruiting, Fuzhou University Affiliated Provincial Hospital; Fuzhou University Affiliated Provincial Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NRG1 (Neuregulin 1) • VEGFA (Vascular endothelial growth factor A) • RNF43 (Ring Finger Protein 43) • TYK2 (Tyrosine Kinase 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • BRAF V600 • MET amplification • RET fusion • FGFR2 mutation • PALB2 mutation • FGFR2 fusion • MET mutation • IDH mutation + BRAF V600E • IDH mutation + NTRK fusion
    3d
    The efficacy and safety of immunoradiotherapy plus gemcitabine, apatinib, and PD-L1 monoclonal antibody as first-line treatment for unresectable biliary tract tumors. (ChiCTR2500111695)
    P=N/A, N=33, Completed, Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital
    New trial
    |
    gemcitabine • AiTan (rivoceranib)
    3d
    A single-arm phase II clinical trial of HIPEC in combination with CRS and durvalumab for the treatment of biliary tract tumors with peritoneal metastases (ChiCTR2500115410)
    P4, N=33, Not yet recruiting, The Third Affiliated Hospital of Naval Medical University; The Third Affiliated Hospital of Naval Medical University
    New P4 trial
    |
    Imfinzi (durvalumab)
    3d
    NIOFA-02: A Randomized, Open-Label Cohort Study of Adebrelimab Combined with NALIRIFOX or Gemcitabine-Cisplatin (GC) as First-Line Treatment for Locally Advanced or Metastatic Biliary Tract Cancer (ChiCTR2600116738)
    P4, N=102, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New P4 trial
    |
    cisplatin • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • AiRuiLi (adebrelimab)
    3d
    Trastuzumab Combined With Chemotherapy and Leflunomide for HER2-Expressing Unresectable Advanced Biliary Tract Malignancies: An Open-Label, Single-Arm, Phase II Study (ChiCTR2500112844)
    P2, N=53, Not yet recruiting, The Third Affiliated Hospital of Naval Medical University (Shanghai Eastern Hepatobiliary Surgery Hospital); The Third Affiliated Hospital of Naval Me
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification • HER-2 expression • HER-2 underexpression
    |
    Herceptin (trastuzumab) • leflunomide
    3d
    Exploratory Study of Disitamab Vedotin Combination Therapy in Advanced Gastrointestinal Tumors with HER2 Overexpression or Amplification (ChiCTR2500114011)
    P2, N=90, Not yet recruiting, The First Affiliated Hospital of Henan University of Chinese Medicine; The First Affiliated Hospital of Henan University of Chinese Medicine
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • RAS wild-type • HER-2 positive + RAS wild-type
    |
    Erbitux (cetuximab) • Perjeta (pertuzumab) • Lenvima (lenvatinib) • Aidixi (disitamab vedotin)
    3d
    Evaluating the Safety and Efficacy of Capecitabine + Finolitimab + Bevacizumab versus Capecitabine as Postoperative Adjuvant Therapy in Biliary Tract Cancer Patients at High Risk of Recurrence:A Randomized, Controlled, Multicenter Phase II Clinical Study (ChiCTR2500112470)
    P2, N=108, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New P2 trial
    |
    Avastin (bevacizumab) • capecitabine
    3d
    A Single-Arm, Single-Center, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) for Second-Line or Later Treatment of Advanced or Metastatic Biliary Tract Cancer (ChiCTR2500112219)
    P2, N=31, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New P2 trial
    |
    Jiataile (sacituzumab tirumotecan)
    3d
    Liposomal Irinotecan Plus 5-FU/LV Compared with Sequential Alternating nab-Paclitaxel Plus S-1 as Second-Line Therapy in Patients with Advanced Biliary Tract Cancer: A Randomized, Open-Label, Prospective Trial (ChiCTR2500111686)
    P2, N=58, Not yet recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
    New P2 trial
    |
    5-fluorouracil • albumin-bound paclitaxel • Teysuno (gimeracil/oteracil/tegafur)
    3d
    Single arm, multi center, open phase Ib/IIa clinical study on the efficacy and safety of JJH201601 liposome for injection in the treatment of advanced pancreatic cancer, biliary tract cancer and hepatocellular carcinoma (ChiCTR2500111729)
    P1/2, N=90, Recruiting, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New P1/2 trial